Experts guarded as breast cancer test gets go-ahead
This article was originally published in Clinica
Oncor's genetic test for predicting whether breast cancer will recur has been approved in the US. But the test should not be used alone when deciding whether to go ahead with post-surgical treatment, recommend experts.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.